Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
Holding ANTX?
Track your performance easily
ANTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $21.40
Previous CloseN/A
Volume42.38K
Average Volume (3M)179.32K
Market Cap
$37.95M
Enterprise Value-$61.50M
Total Cash (Recent Filing)$4.07M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Mar 27, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding29,878,890
10 Day Avg. Volume109,734
30 Day Avg. Volume179,324
Standard Deviation0.36
R-Squared0.00063
Alpha0.00337
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.96
Forecast
1Y Price Target
$2.67Price Target Upside110.24% Upside
Rating ConsensusHold
Number of Analyst Covering4
AN2 Therapeutics, Inc. News
PremiumCompany Announcements
AN2 Therapeutics Promotes Joshua Eizen to Key Roles
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEpetraborole showed a statistically significant and clinically meaningful improvement in a quality of life measure compared to placebo, even in patients with advanced and severe disease.
Financial StrategyThe company announced a planned 50% reduction in workforce to be complete by YE, resulting in a cash runway through 2027, beyond multiple catalysts expected from the pipeline.
Research And DevelopmentResearch and development continue with the company's boron-chemistry platform, aiming to announce up to three new development candidates in 2025.
Bears Say
Clinical TrialsEpetraborole did not show a difference in culture conversion relative to placebo in Phase 2, causing shares to tumble and a shift in focus to other pipeline programs.
Financial PerformanceAN2 reported a net loss of $12.7M for 3Q24, with a loss per share of $0.43.
Stock RatingThe analyst downgraded the stock to Hold due to conservative expectations for the lead driver EBO-301's ability to advance in r/r NTM.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $0.87 and its highest was $21.40 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
AN2 Therapeutics, Inc.’s market cap is $37.95M.
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 68 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.02.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -0.27.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,878,890 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANTX
---
AN2 Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.67 (110.24% Upside)
$2.67 (110.24% Upside)
Hedge Fund Trend
Decreased
By 3.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $465.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.90%
12-Months-Change
Fundamentals
Return on Equity
-53.56%
Trailing 12-Months
Asset Growth
-36.49%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Month Forecast
Average Price Target
$2.67
▲(110.24% Upside)
Technical Analysis
Acurx Pharmaceuticals
―
Applied Therapeutics
―
Corbus Pharmaceuticals
―
Evolus
―
Regulus
―
Axsome Therapeutics
―
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-24.20%
reiterated a buy rating 2 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -24.20% per trade.
---